Developmental Current and Future Therapy for Severe Asthma

Publisher： Bentham Science Publishers

E-ISSN： 2212-4055|12|1|54-60

ISSN： 1871-5281

Source： Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets - Inflammation & Allergy), Vol.12, Iss.1, 2013-02, pp. : 54-60

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Challenges in the Management of Severe Asthma: Role of Current and Future Therapies

By  

Current Pharmaceutical Design, Vol. 17, Iss. 7, 2011-03 ,pp. : 703-711

Bentham Science Publishers

Access to resources Recommend Favorite

Steroid Resistance in Severe Asthma: Current Mechanisms and Future Treatment

By  

Current Pharmaceutical Design, Vol. 17, Iss. 7, 2011-03 ,pp. : 674-684

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-IgE Therapy with Omalizumab for Severe Asthma: Current Concepts and Potential Developments

By  

Current Drug Targets, Vol. 16, Iss. 2, 2015-02 ,pp. : 171-178

Bentham Science Publishers

Access to resources Recommend Favorite

Genetic Analyses in Asthma: Current Concepts and Future Directions

By Hakonarson H.  

American Journal of PharmacoGenomics, Vol. 2, Iss. 3, 2002-01 ,pp. : 155-166

Adis International

Access to resources Recommend Favorite

Omalizumab is an effective add-on therapy in moderate-to-severe allergic asthma

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 21, Iss. 7, 2005-07 ,pp. : 1-4

Adis International

Access to resources Recommend Favorite